- Home
- ETNB
ETNB
89bio Inc.
as 11-15-2024 4:00pm EST
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 867.4M | IPO Year: | 2019 |
| Target Price: | $30.33 | AVG Volume (30 days): | 901.8K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.00 - $16.63 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 133.30% |
Latest 89bio Inc. News
ETNB Breaking Stock News: Dive into ETNB Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
GlobeNewswire
4 days ago
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
5 days ago
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
10 days ago
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire
12 days ago
89bio to Participate in the UBS Global Healthcare Conference
TipRanks
15 days ago
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
Investor's Business Daily
16 days ago
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
GuruFocus.com
a month ago
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings
Compare ETNB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ETNB 89bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.